- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01247467
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study
January 21, 2014 updated by: National University Hospital, Singapore
A number of prognostic and/or predictive genomic signatures for breast cancer have been developed by Genome Institute of Singapore (GIS).
In the past 1 year, GIS has developed protocols and methods to conduct expression assays from formalin-fixed, paraffin-embedded (FFPE) tumor specimens.
A study on 800 tumor samples is planned to analyze these gene signatures and compare them with conventional clinical prognosticators and predictors.
As the investigators plan to use archival tumor samples that dates back to the 1990s, the aim of this pilot study is to first analyze 10 anonymized samples to determine the feasibility of running these assays on old archival blocks.
The information generated will help us determine whether very old samples (diagnosed before 2000) may be selected for the actual study.
Study Overview
Detailed Description
Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens).
Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data.
8-10 ten-micron sections will be cut from each tumor block.
RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit.
RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay.
RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore.
Study Type
Observational
Enrollment (Anticipated)
10
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore
- National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Archival tumor samples that dates back to the 1990s
Description
Inclusion Criteria:
- Half of these blocks will be from breast cancer patients who were diagnosed before year 2000.
- Half of the blocks will be from breast cancer patients diagnosed between year 2000-2005 (control specimens).
Exclusion Criteria:
- Breast cancer patients diagnosed after year 2005.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast Tumor
Breast Tumor Blocks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Soo Chin Lee, MBBS, MRCP, National University Hospital, Singapore
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010 May;121(1):121-31. doi: 10.1007/s10549-010-0788-0. Epub 2010 Mar 26.
- Lim YW, Goh BC, Wang LZ, Tan SH, Chuah BYS, Lim SE, Iau P, Buhari SA, Chan CW, Sukri NB, Cordero MT, Soo R, Lee SC. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. Ann Oncol. 2010 Nov;21(11):2175-2182. doi: 10.1093/annonc/mdq230. Epub 2010 Apr 29.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
August 26, 2010
First Submitted That Met QC Criteria
November 23, 2010
First Posted (Estimate)
November 24, 2010
Study Record Updates
Last Update Posted (Estimate)
January 22, 2014
Last Update Submitted That Met QC Criteria
January 21, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR04/21/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Tumor
-
Carebot s.r.o.CompletedBreast Cancer | Breast Tumor BenignCzechia
-
National University Hospital, SingaporeUnknownBreast Tumor TissueSingapore
-
KK Women's and Children's HospitalRecruiting
-
Relay Therapeutics, Inc.CompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA MutationUnited States
-
University of Alabama at BirminghamBracco CorporateCompletedBreast Malignant Tumor | Breast Benign TumorUnited States
-
University Hospital, ToursInstitut Cancerologie de l'OuestTerminatedMetastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative TumorFrance
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaRecruitingBreast Cancer | Breast Tumor | Mammary Cancer | Mammary TumorChile
-
Nuvation Bio Inc.WithdrawnBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the BreastUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the Breast | Tumors, BreastUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
Clinical Trials on Breast Tumor Blocks
-
National University Hospital, SingaporeUnknown
-
Duke UniversityTerminatedAdvanced Breast CancerUnited States
-
National Cancer Institute, ThailandVichaiyut HospitalWithdrawnCarcinoma Breast Stage IVThailand
-
Shanghai Zhongshan HospitalUnknownGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks
-
Samsung Medical CenterRecruitingBreast CancerKorea, Republic of
-
Tongji HospitalThe First Affiliated Hospital with Nanjing Medical University; Qilu Hospital... and other collaboratorsNot yet recruitingBreast Neoplasm Female
-
Jules Bordet InstituteCompletedInvasive Breast CancerBelgium
-
Alexander StessinNorthwell HealthRecruitingBreast Cancer | Breast AdenocarcinomaUnited States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina